Take a look at Amgen’s Repatha and Sanofi and Regeneron’s Praluent, two new cholesterol-lowering drugs launched with high expectations and a high price tag! After a value-based price contract, many questions have arisen as to the patients responsibility to correctly adhere to their prescription regimens. Read more here. (Source: Ned Pagliarulo, BioPharmaDIVE, 5/15/17)
You are here: / / How Will Value-Based Deals Hold Up Without Patient Adherence?